Oncobit and ID Solutions working on faster cancer tests

(CONNECT) Oncobit AG, a spin-off from the University of Zurich that is active in the field of precision oncology, is joining forces with ID Solutions from Montpellier in southern France, as detailed in a statement. ID Solutions offers digital PCR-based oncology diagnostics. Oncobit will contribute its monitoring assays and analytical software to this partnership. Together, the two companies will seek to develop faster cancer tests that comply with European regulations for clinical diagnostics (In Vitro Diagnostic Regulation - IVDR).

In specific terms, this new generation of cancer tests should be able to identify key genetic biomarkers within 24 hours that are crucial for targeted cancer therapy. As such, physicians would be in a position to rapidly determine the most suitable treatment approach. Furthermore, treatment monitoring on the basis of quantifying tumor-derived biomarkers in the blood should allow for timely and precise adjustments to the treatment.

“By partnering with Oncobit, we are taking a major step toward bringing digital PCR into clinical oncology diagnostics and patient monitoring”, as Lise Grewis, President of ID Solutions, comments in the statement. With this partnership, the two companies are seeking to make significant progress in the fight against cancer. “This partnership reflects our shared vision of making personalized oncology care accessible worldwide”, according to Dr. Claudia Scheckel, CEO of Oncobit AG, who adds: “By combining our complementary expertise, we are equipping clinicians with precision tools that set new standards in sensitivity, reliability, and patient monitoring”. ce/jh